157 related articles for article (PubMed ID: 2073118)
1. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.
Fass RJ; Gregory WW; D'Amato RF; Matsen JM; Wright DN; Young LS
Antimicrob Agents Chemother; 1990 Nov; 34(11):2256-9. PubMed ID: 2073118
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam.
Knapp CC; Sierra-Madero J; Washington JA
Diagn Microbiol Infect Dis; 1990; 13(1):45-9. PubMed ID: 2331849
[TBL] [Abstract][Full Text] [Related]
3. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
Jones RN; Barry AL; Thornsberry C; Wilson HW
Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
[TBL] [Abstract][Full Text] [Related]
4. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.
Barry AL; Jones RN
J Clin Microbiol; 1988 Jan; 26(1):13-7. PubMed ID: 3343304
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.
Jones RN; Barry AL; Packer RR; Gregory WW; Thornsberry C
J Clin Microbiol; 1987 Sep; 25(9):1725-9. PubMed ID: 3498740
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.
Jones RN; Wilson HW; Thornsberry C; Barry AL
Diagn Microbiol Infect Dis; 1985 Nov; 3(6):489-99. PubMed ID: 2998694
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.
Eliopoulos GM; Klimm K; Ferraro MJ; Moellering RC
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):624-6. PubMed ID: 2506024
[TBL] [Abstract][Full Text] [Related]
8. Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.
Hardy DJ; Barry AL; Fuchs PC; Gerlach EH; McLaughlin JC; Pfaller MA
Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):926-30. PubMed ID: 1486889
[TBL] [Abstract][Full Text] [Related]
9. Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.
Bradford PA; Sanders CC
Antimicrob Agents Chemother; 1992 Feb; 36(2):394-400. PubMed ID: 1605604
[TBL] [Abstract][Full Text] [Related]
10. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Turk Dagi H; Kus H; Arslan U; Tuncer I
Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefoperazone/sulbactam and other antimicrobials against anaerobic bacteria.
D'Amato RF; Hochstein L; Frankel H
Diagn Microbiol Infect Dis; 1990; 13(1):51-5. PubMed ID: 2331850
[TBL] [Abstract][Full Text] [Related]
12. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
Thomson KS; Weber DA; Sanders CC; Sanders WE
Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
[TBL] [Abstract][Full Text] [Related]
13. [Clinical laboratory approach for estimating effective administrative dose of sulbactam/cefoperazone].
Uete T; Matsuo K
Jpn J Antibiot; 1988 Nov; 41(11):1578-90. PubMed ID: 3210296
[TBL] [Abstract][Full Text] [Related]
14. [Effects of sulbactam on the activity of cefoperazone against various clinical isolates].
Uete T; Matsuo K
Jpn J Antibiot; 1989 Apr; 42(4):896-909. PubMed ID: 2769941
[TBL] [Abstract][Full Text] [Related]
15. In vitro comparison of cefoperazone/sulbactam with selected antimicrobials against 300 bacteroides isolates. Inhibitory activity and time-kill kinetic studies.
Gelfand MS; Grogan JT; Haas MJ
Diagn Microbiol Infect Dis; 1989; 12(5):421-8. PubMed ID: 2612130
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of cefoperazone and cefoperazone plus sulbactam in a neutropenic site model.
Fasching CE; Moody JA; Sinn LM; Tenquist J; Gerding DN; Peterson LR
Diagn Microbiol Infect Dis; 1991; 14(2):147-55. PubMed ID: 1873973
[TBL] [Abstract][Full Text] [Related]
17. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.
Williams JD
Clin Infect Dis; 1997 Mar; 24(3):494-7. PubMed ID: 9114205
[TBL] [Abstract][Full Text] [Related]
18. Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?
Ku YH; Yu WL
Infect Genet Evol; 2021 Mar; 88():104707. PubMed ID: 33418147
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii.
Pei G; Mao Y; Sun Y
Microb Drug Resist; 2012 Dec; 18(6):574-7. PubMed ID: 22928863
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).
Pfaller MA; Flamm RK; Duncan LR; Mendes RE; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):177-183. PubMed ID: 28341098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
